Elekta to work with academics on AI-directed radiotherapyRadiotherapy specialist Elekta has joined forces with two academic groups in the Netherlands to explore the use of Share XElekta to work with academics on AI-directed radiotherapyhttps://pharmaphorum.com/news/elekta-to-work-with-academics-on-ai-directed-radiotherapy/
What HCPs think about health equity in cancer careAfter more than a year of COVID-19 dominating health conversations, HCPs have been engaging in dialogue about continually Share XWhat HCPs think about health equity in cancer carehttps://pharmaphorum.com/views-and-analysis/what-hcps-think-about-health-equity-in-cancer-care/
Health Innovators: Eliot Forster, F-StarIn this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Eliot Forster, CEO of F-Star – a clinical-stage, Share XHealth Innovators: Eliot Forster, F-Starhttps://pharmaphorum.com/views-analysis-oncology/health-innovators-eliot-forster-f-star/
Country focus: China & APAC’s growing medical needs bring opportunities and challengesDr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma Share XCountry focus: China & APAC’s growing medical needs bring opportunities and challengeshttps://pharmaphorum.com/oncology/country-focus-china-apacs-growing-medical-needs-bring-opportunities-and-challenges/
Changing focus to cachexia may be key to improved cancer outcomesCachexia could be the next blockbuster area in cancer therapeutics because of its link to survival outcomes. Physician Share XChanging focus to cachexia may be key to improved cancer outcomeshttps://pharmaphorum.com/views-analysis-oncology/changing-focus-to-cachexia-may-be-key-to-improved-cancer-outcomes/
LAG-3 drugs take centre stage at ASCO, showing potential as next-gen immunotherapiesLAG-3 drugs from arch-rivals Bristol-Myers Squibb and Merck & Co look set to become talking points at this Share XLAG-3 drugs take centre stage at ASCO, showing potential as next-gen immunotherapieshttps://pharmaphorum.com/news/bms-lag3-combination-outperforms-opdivo-in-advanced-melanoma-trial/
Numab raises $110m to develop cancer bispecific antibodiesSwitzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to Share XNumab raises $110m to develop cancer bispecific antibodieshttps://pharmaphorum.com/news/numab-raises-110m-to-develop-cancer-bispecific-antibodies/
FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy optionThe FDA has accepted Eli Lilly and China’s Innovent filing for their latecomer immunotherapy sintilimab, which is expected Share XFDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy optionhttps://pharmaphorum.com/news/fda-review-of-lilly-innovents-sintilimab-paves-way-for-cut-price-immunotherapy-option/
BMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drugBristol-Myers Squibb has paid $200 million, and promised up to $1.36 billion in “biobucks” for exclusive rights to Share XBMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drughttps://pharmaphorum.com/news/bms-agrees-deal-worth-up-to-1-56bn-for-agenus-tigit-cancer-drug/
